Cetuximab

also known as Erbitux · C-225 · CTX · Cetuximab (Erbitux) · CMAB009 · ERBITUX (cetuximab) · IMC-C225 · NSC #714692 · +10 more

Monoclonal antibody targets EGFR via inhibition

Developed for: colorectal cancer · head and neck squamous cell carcinoma · non-small cell lung carcinoma · head and neck cancer · cancer · esophageal cancer · oropharynx squamous cell carcinoma · gastric cancer
+181 more
· malignant pancreatic neoplasm · metastasis from malignant tumor of colon · rectal cancer · hypopharynx squamous cell carcinoma · neoplasm · lung cancer · metastatic malignant neoplasm · metastatic neoplasm · squamous cell carcinoma · breast cancer · colorectal adenocarcinoma · colorectal carcinoma · nasopharyngeal carcinoma · pancreatic ductal adenocarcinoma · colorectal neoplasm · rectum adenocarcinoma · colon adenocarcinoma · colon carcinoma · metastatic squamous cell carcinoma · nasal cavity and paranasal sinus squamous cell carcinoma · nasopharyngeal squamous cell carcinoma · head and neck neoplasm · larynx verrucous carcinoma · cancer of unknown primary site · oral cavity squamous cell carcinoma · verrucous carcinoma of oral cavity · oropharyngeal carcinoma · skin squamous cell carcinoma · tongue cancer · esophageal squamous cell carcinoma · glioblastoma · laryngeal squamous cell carcinoma · oral cavity cancer · ovarian cancer · rectal carcinoma · cervical cancer · esophageal adenocarcinoma · malignant colon neoplasm · pancreatic adenocarcinoma · salivary gland squamous cell carcinoma · adenoid cystic carcinoma · anaplastic astrocytoma · hepatocellular carcinoma · larynx cancer · lung adenocarcinoma · anal carcinoma · cholangiocarcinoma · colon mucinous adenocarcinoma · colon signet ring cell adenocarcinoma · esthesioneuroblastoma · gallbladder cancer · high grade malignant neoplasm · hypopharynx cancer · inverted papilloma · laryngeal carcinoma · lung large cell carcinoma · lymphoepithelial-like carcinoma · nasal cavity and paranasal sinus lethal midline granuloma · oral cavity mucoepidermoid carcinoma · precancerous condition · renal cell carcinoma · salivary gland cancer · triple-negative breast carcinoma · adenosquamous lung carcinoma · brain cancer · breast carcinoma · carcinoma of lip · carcinoma of pharynx · cervical squamous cell carcinoma · chordoma · endometrial cancer · fibrillary astrocytoma · gastric adenocarcinoma · gastroesophageal junction adenocarcinoma · HER2 positive breast carcinoma · hypopharyngeal carcinoma · lip and oral cavity carcinoma · lip and oral cavity squamous cell carcinoma · liver cancer · metastatic malignant neoplasm in the colon · neoplastic disease or syndrome · non-small cell squamous lung carcinoma · oral cavity neoplasm · oropharynx cancer · pancreatic neoplasm · pharynx neoplasm · plasma cell myeloma · primary peritoneal carcinoma · rectal signet ring cell adenocarcinoma · rectum mucinous adenocarcinoma · sarcoma · urinary bladder cancer · urothelial carcinoma · acute myeloid leukemia, KRAS gene mutation · adenocarcinoma · adenosquamous carcinoma · anal canal cancer · anal squamous cell carcinoma · anaplastic oligoastrocytoma · anus cancer · appendix cancer · appendix carcinoma · basaloid carcinoma · basaloid squamous cell carcinoma · bile duct cancer · biliary tract cancer · breast neoplasm · carcinoid tumor · carcinoma · carcinoma of esophagus · Castleman disease · castration-resistant prostate carcinoma · cervical adenosquamous carcinoma · cervical carcinoma · cervical small cell carcinoma · colonic neoplasm · colorectal cancer, susceptibility to, 4 · complex regional pain syndrome · diffuse intrinsic pontine glioma · diffuse midline glioma, H3 K27M-mutant · endometrial carcinoma · Erdheim-Chester disease · extrahepatic bile duct carcinoma · fallopian tube neoplasm · female breast carcinoma · female reproductive system neoplasm · gallbladder adenocarcinoma · gastroesophageal adenocarcinoma · gastrointestinal stromal tumor · head and neck carcinoma · kidney cancer · laryngeal neoplasm · liver and intrahepatic bile duct neoplasm · lung carcinoma · lymphangioleiomyomatosis · major salivary gland carcinoma · male reproductive system neoplasm · malignant glioma · malignant tumor of neck · mesothelial neoplasm · metastatic melanoma · nasal cavity and paranasal sinus carcinoma · nasal cavity cancer · nasal cavity neoplasm · nasal cavity squamous cell carcinoma · neoplasm of esophagus · neuralgia · NF2-related schwannomatosis · oligoastrocytoma · oligodendroglioma · pancreas disorder · paranasal sinus cancer · paranasal sinus neoplasm · paranasal sinus squamous cell carcinoma · peritoneal neoplasm · pharynx cancer · pilomyxoid astrocytoma · prostate cancer · prostate carcinoma · rectal neoplasm · respiratory system cancer · respiratory tract neoplasm · skin basal cell carcinoma · skin neoplasm · small intestine adenocarcinoma · small intestine cancer · small intestine leiomyosarcoma · small intestine lymphoma · soft tissue sarcoma · squamous cell carcinoma of lip · squamous cell carcinoma of penis · squamous cell lung carcinoma · thymic carcinoma · thymoma · thyroid gland carcinoma · tongue carcinoma · undifferentiated carcinoma · undifferentiated carcinoma of nasopharynx · urothelial neoplasm · mucinous adenocarcinoma · refractory malignant neoplasm
Investigated by: National Cancer Institute (NCI) · Bristol-Myers Squibb · Eli Lilly and Company · Merck Sharp & Dohme LLC · Merck KGaA, Darmstadt, Germany · M.D. Anderson Cancer Center
+523 more
· Fudan University · Pfizer · Sanofi · Memorial Sloan Kettering Cancer Center · Dana-Farber Cancer Institute · Sun Yat-sen University · Alliance for Clinical Trials in Oncology · Celgene Corporation · Eastern Cooperative Oncology Group · Washington University School of Medicine · Merck Serono International SA · SWOG Cancer Research Network · Gruppo Oncologico del Nord-Ovest · Hoffmann-La Roche · UNC Lineberger Comprehensive Cancer Center · UNICANCER · Gustave Roussy, Cancer Campus, Grand Paris · ImmunityBio, Inc. · NRG Oncology · Novartis Pharmaceuticals · University of Chicago · AstraZeneca · Beth Israel Deaconess Medical Center · Boehringer Ingelheim · Brigham and Women's Hospital · Groupe Oncologie Radiotherapie Tete et Cou · Massachusetts General Hospital · Radiation Therapy Oncology Group · Second Affiliated Hospital, School of Medicine, Zhejiang University · Fate Therapeutics · Federation Francophone de Cancerologie Digestive · Fox Chase Cancer Center · Roche Pharma AG · Ruijin Hospital · Shanghai Zhongshan Hospital · Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) · University of Michigan Rogel Cancer Center · GERCOR - Multidisciplinary Oncology Cooperative Group · Georgetown University · Gynecologic Oncology Group · Heidelberg University · Jiangsu Cancer Institute & Hospital · NSABP Foundation Inc · Northwell Health · Odense University Hospital · Regeneron Pharmaceuticals · RenJi Hospital · Shanghai Jiao Tong University School of Medicine · Spanish Head And Neck Cancer Cooperative Group · Swiss Cancer Institute · US Oncology Research · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · University Hospital of Crete · University of Campania Luigi Vanvitelli · University of Colorado, Denver · University of Pittsburgh · University of Wisconsin, Madison · AIO-Studien-gGmbH · Bayer · Cancer and Leukemia Group B · Chang Gung Memorial Hospital · City Clinical Oncology Hospital No 1 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · European Organisation for Research and Treatment of Cancer - EORTC · Fujian Cancer Hospital · Genentech, Inc. · Genfleet Therapeutics (Shanghai) Inc. · Gilead Sciences · H. Lee Moffitt Cancer Center and Research Institute · Institute of Oncology Ljubljana · Merck, S.L., Spain · Moscow Multidisciplinary Clinical Center "Kommunarka" · NCIC Clinical Trials Group · all 529 on the full record

Regulatory milestones approvals, filings & regulatory actions · 8 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (6)	US (FDA)	ERBITUX	—	2006-03-01 – 2021-09-24	fda.gov ↗
Approved	EU (EMA)	Erbitux	—	2004-06-29	europa.eu ↗
Approved	US (FDA)	ERBITUX	—	2004-02-12	fda.gov ↗

Trials 776 · started per year

today

US approved 2004

EU approved 2004

199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 04 trials
Phase 0	NCT05816785	Apr 2023 → Aug 2026	head and neck squamous cell carcinoma	University of Wisconsin, Madison	Completed	No outcome recorded
Phase 0	NCT04065555	Oct 2020 → Jun 2022	head and neck cancer	Presage Biosciences	Completed	No outcome recorded
Phase 0	NCT00835679	Dec 2009 → Feb 2011	colon mucinous adenocarcinoma, colon signet ring cell adenocarcinoma, metastasis from malignant tumor of colon, rectal signet ring cell adenocarcinoma +1	National Cancer Institute (NCI)	Terminated	No outcome recorded
Phase 0	NCT00757549	Sep 2008 → Aug 2011	head and neck cancer	Mayo Clinic	Completed	No outcome recorded
Phase 1130 trials · 1 met primary
Phase 1	NCT07746141	Sep 2026 → Sep 2028 expected	metastatic malignant neoplasm	BeOne Medicines	Recruiting	No outcome recorded
Phase 1	NCT07543471	Jun 2026 → Jun 2027 expected	colorectal cancer	Shanghai Henlius Biotech	Not yet recruiting	No outcome recorded
Phase 1	NCT07535112	Apr 2026 → Jul 2029 expected	colorectal adenocarcinoma	Bayer	Recruiting	No outcome recorded
Phase 1	NCT07349537	Jan 2026 → Apr 2028 expected	colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma	Revolution Medicines, Inc.	Recruiting	No outcome recorded
Phase 1	NCT07247110	Dec 2025 → Dec 2030 expected	cancer	Merck Sharp & Dohme LLC	Recruiting	No outcome recorded
Phase 1	NCT07216105	Nov 2025 → Jan 2028 expected	breast cancer, colorectal cancer, endometrial carcinoma, head and neck squamous cell carcinoma +2	Fate Therapeutics	Recruiting	No outcome recorded
Phase 1	NCT06806852	May 2025 → Aug 2027 expected	head and neck squamous cell carcinoma	Boehringer Ingelheim	Active not recruiting	No outcome recorded
Phase 1	NCT06917079	Mar 2025 → Aug 2027 expected	colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	Recruiting	No outcome recorded
Phase 1	NCT06764771	Mar 2025 → Oct 2027 expected	cancer	Bristol-Myers Squibb	Recruiting	No outcome recorded
Phase 1	NCT06835569	Mar 2025 → May 2029 expected	colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma	Alterome Therapeutics, Inc.	Recruiting	No outcome recorded
Show all 130 trials opens the full record — a long page
Phase 1/2101 trials · 3 missed
Phase 1/2	NCT07863869	Sep 2026 → May 2029 expected	colorectal cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Not yet recruiting	No outcome recorded
Phase 1/2	NCT07468071	Jun 2026 → Jun 2029 expected	—	Novartis Pharmaceuticals	Active not recruiting	No outcome recorded
Phase 1/2	NCT07286149	Apr 2026 → Aug 2029 expected	lung cancer	Merck Sharp & Dohme LLC	Recruiting	No outcome recorded
Phase 1/2	NCT07397338	Jan 2026 → May 2029 expected	colorectal cancer, metastatic neoplasm, non-small cell lung carcinoma	Revolution Medicines, Inc.	Recruiting	No outcome recorded
Phase 1/2	NCT07223047	Nov 2025 → Oct 2028 expected	colorectal cancer, high grade malignant neoplasm, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma	Bristol-Myers Squibb	Recruiting	No outcome recorded
Phase 1/2	NCT07259590	Oct 2025 → Jul 2027 expected	colorectal cancer, pancreatic ductal adenocarcinoma	Genfleet Therapeutics (Shanghai) Inc.	Recruiting	No outcome recorded
Phase 1/2	NCT07059221	Jul 2025 → Mar 2027 expected	head and neck squamous cell carcinoma	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Recruiting	No outcome recorded
Phase 1/2	NCT05956821	Jun 2025 → Oct 2029 expected	anaplastic astrocytoma, diffuse midline glioma, H3 K27M-mutant, fibrillary astrocytoma, glioblastoma +1	University of Miami	Recruiting	No outcome recorded
Phase 1/2	NCT07012954	Jun 2025 → Dec 2027 expected	colorectal cancer	Sun Yat-sen University	Recruiting	No outcome recorded
Phase 1/2	NCT06943820	May 2025 → Dec 2026 expected	colorectal adenocarcinoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma	Akeso	Recruiting	No outcome recorded
Phase 1/2	NCT06412198	Aug 2024 → Mar 2029 expected	colorectal cancer	M.D. Anderson Cancer Center	Recruiting	No outcome recorded
Phase 1/2	NCT06385678	Jul 2024 → Dec 2025 overdue	—	Jiangsu HengRui Medicine Co., Ltd.	Active not recruiting	No outcome recorded
Phase 1/2	NCT06379399	Apr 2024 → Mar 2025	colorectal cancer	Wangxia LV	Unknown	No outcome recorded
Phase 1/2	NCT05910827	Feb 2024 → Dec 2027 expected	cervical squamous cell carcinoma, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, nasopharyngeal carcinoma +2	Hummingbird Bioscience	Recruiting	No outcome recorded
Phase 1/2	NCT06024174	Nov 2023 → May 2024	cancer	Bristol-Myers Squibb	Terminated	No outcome recorded Stop: Business
Phase 1/2	NCT05756153	Apr 2023 → Apr 2025	non-small cell lung carcinoma	Genfleet Therapeutics (Shanghai) Inc.	Completed	No outcome recorded
Phase 1/2	NCT05775900	Feb 2023 → Jul 2025	colorectal cancer	Sun Yat-sen University	Completed	No outcome recorded
Phase 1/2	NCT05584670	Nov 2022 → Jan 2027 expected	cancer	Sanofi	Recruiting	No outcome recorded
Phase 1/2	NCT05358249	Oct 2022 → Sep 2026 overdue	colorectal carcinoma, non-small cell lung carcinoma	Novartis Pharmaceuticals	Active not recruiting	No outcome recorded
Phase 1/2	NCT05200442	Aug 2022 → May 2027	colorectal adenocarcinoma	University of Chicago	Suspended	No outcome recorded Stop: Enrollment
Phase 1/2	NCT05410145	Aug 2022 → Apr 2027 expected	acute myeloid leukemia, KRAS gene mutation	D3 Bio (Wuxi) Co., Ltd	Recruiting	No outcome recorded
Phase 1/2	NCT05289076	May 2022 → Mar 2024	chemotherapy-induced toxicity, colorectal cancer, metastatic neoplasm	University Hospital, Linkoeping	Unknown	No outcome recorded
Phase 1/2	NCT05194995	Feb 2022 → Apr 2025 overdue	appendix cancer, small intestine cancer	Allist Pharmaceuticals, Inc.	Active not recruiting	No outcome recorded
Phase 1/2	NCT05039177	Sep 2021 → Aug 2025	colorectal cancer, pancreatic ductal adenocarcinoma	Erasca, Inc.	Completed	No outcome recorded
Phase 1/2	NCT05002270	Sep 2021 → Feb 2025	non-small cell lung carcinoma	Jacobio Pharmaceuticals Co., Ltd.	Completed	No outcome recorded
Phase 1/2	NCT04956640	Jul 2021 → Apr 2027 expected	biliary tract neoplasm, colorectal neoplasm, endometrium neoplasm, non-small cell lung carcinoma +2	Eli Lilly and Company	Active not recruiting	No outcome recorded
Phase 1/2	NCT04872634	Jul 2021 → May 2023	non-small cell lung carcinoma	NKMAX Co., Ltd.	Unknown	No outcome recorded
Phase 1/2	NCT04717375	Apr 2021 → Jul 2025	cancer	Sanofi	Terminated	No outcome recorded Stop: Business
Phase 1/2	NCT04856631	Apr 2021 → Nov 2022	head and neck squamous cell carcinoma	Shanghai Junshi Bioscience Co., Ltd.	Unknown	No outcome recorded
Phase 1/2	NCT04464967	Mar 2021 → Aug 2022	HER2 positive breast carcinoma, cervical cancer, colorectal cancer, endometrial cancer +9	NKGen Biotech, Inc.	Withdrawn	No outcome recorded
Phase 1/2	NCT04616183	Dec 2020 → Dec 2028 expected	colon adenocarcinoma, rectum adenocarcinoma	M.D. Anderson Cancer Center	Active not recruiting	No outcome recorded
Phase 1/2	NCT04585035	Oct 2020 → Apr 2024 overdue	non-small cell lung carcinoma	InventisBio Co., Ltd	Active not recruiting	No outcome recorded
Phase 1/2	NCT04474470	Sep 2020 → May 2024	colorectal adenocarcinoma, head and neck squamous cell carcinoma, metastatic neoplasm	TyrNovo Ltd.	Completed	No outcome recorded
Phase 1/2	NCT04790448	Jul 2020 → Dec 2021	colorectal cancer	Sun Yat-sen University	Completed	No outcome recorded
Phase 1/2	NCT04495621	Jul 2020 → Jan 2024	colorectal cancer	Menarini Group	Completed	No outcome recorded
Phase 1/2	NCT04349267	Jul 2020 → Aug 2024	neoplasm	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1/2	NCT04009681	Jun 2019 → Dec 2025	metastatic neoplasm	Synthorx, Inc, a Sanofi company	Terminated	No outcome recorded Stop: Business
Phase 1/2	NCT04017650	Jun 2019 → Dec 2027 expected	colon adenocarcinoma, rectum adenocarcinoma	M.D. Anderson Cancer Center	Active not recruiting	No outcome recorded
Phase 1/2	NCT03785249	Jan 2019 → Dec 2026 expected	metastatic malignant neoplasm	Mirati Therapeutics Inc.	Active not recruiting	No outcome recorded
Phase 1/2	NCT03428958	Oct 2018 → Mar 2024	colorectal carcinoma	NuCana plc	Completed	No outcome recorded
Phase 1/2	NCT03563157	Sep 2018 → Apr 2019	colorectal cancer	ImmunityBio, Inc.	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT03647423	Aug 2018 → Aug 2020	chordoma	ImmunityBio, Inc.	Withdrawn	No outcome recorded
Phase 1/2	NCT03169777	Aug 2018 → Jan 2019	colorectal cancer	ImmunityBio, Inc.	Withdrawn	No outcome recorded
Phase 1/2	NCT03563170	May 2018 → Aug 2019	hepatocellular carcinoma	ImmunityBio, Inc.	Withdrawn	No outcome recorded Stop: Enrollment
Phase 1/2	NCT03387111	Jan 2018 → Apr 2019	squamous cell carcinoma	ImmunityBio, Inc.	Terminated	No outcome recorded
Phase 1/2	NCT03051906	Jan 2018 → Jan 2022	head and neck neoplasm	Careggi University Hospital	Unknown	No outcome recorded
Phase 1/2	NCT03370276	Dec 2017 → Sep 2021	hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma +1	H. Lee Moffitt Cancer Center and Research Institute	Completed	No outcome recorded
Phase 1/2	NCT03169764	Dec 2017 → Jan 2019	head and neck squamous cell carcinoma	ImmunityBio, Inc.	Withdrawn	No outcome recorded
Phase 1/2	NCT03024489	Jul 2017 → Mar 2024	head and neck squamous cell carcinoma	Mahidol University	Unknown	No outcome recorded
Phase 1/2	NCT02953782	Nov 2016 → Feb 2020	colorectal cancer	Gilead Sciences	Completed	No outcome recorded
Phase 1/2	NCT02713373	Aug 2016 → Jul 2020	colorectal carcinoma	Roswell Park Cancer Institute	Completed	No outcome recorded
Phase 1/2	NCT02054442	Aug 2016 → Dec 2021	head and neck squamous cell carcinoma	Radboud University Medical Center	Unknown	No outcome recorded
Phase 1/2	NCT02298595	Aug 2016 → Aug 2019	oropharynx squamous cell carcinoma	Julie E. Bauman, MD, MPH	Withdrawn	No outcome recorded
Phase 1/2	NCT02845856	Jul 2016 → Jul 2017	non-small cell lung carcinoma	Fuda Cancer Hospital, Guangzhou	Completed	No outcome recorded
Phase 1/2	NCT02822482	Jun 2016 → Oct 2019	head and neck squamous cell carcinoma	UNICANCER	Terminated	No outcome recorded
Phase 1/2	NCT02861898	Jun 2016 → Dec 2028 expected	brain cancer, glioblastoma	Northwell Health	Recruiting	No outcome recorded
Phase 1/2	NCT02599324	Dec 2015 → Aug 2021	colorectal adenocarcinoma, gastric adenocarcinoma, renal cell carcinoma, urothelial carcinoma	Pharmacyclics LLC.	Completed	No outcome recorded
Phase 1/2	NCT02643550	Dec 2015 → Mar 2023	head and neck neoplasm	Innate Pharma	Completed	No outcome recorded
Phase 1/2	NCT02507154	Jul 2015 → Aug 2019	head and neck squamous cell carcinoma, nasopharyngeal carcinoma	National University Hospital, Singapore	Unknown	No outcome recorded
Phase 1/2	NCT02143622	Mar 2015 → Aug 2018	head and neck squamous cell carcinoma	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 1/2	NCT02278133	Dec 2014 → May 2016	colorectal cancer	Array BioPharma	Completed	No outcome recorded
Phase 1/2	NCT02318901	Oct 2014 → Aug 2018	breast cancer, cancer of unknown primary site, colorectal cancer, esophageal cancer +1	Western Regional Medical Center	Terminated	No outcome recorded
Phase 1/2	NCT02101034	Jun 2014 → Jun 2020	head and neck squamous cell carcinoma	Washington University School of Medicine	Completed	No outcome recorded
Phase 1/2	NCT02117466	Apr 2014 → Jan 2021	colorectal cancer	Amsterdam UMC, location VUmc	Terminated	No outcome recorded
Phase 1/2	NCT01960023	Oct 2013 → Jul 2016	colorectal cancer	NSABP Foundation Inc	Withdrawn	No outcome recorded
Phase 1/2	NCT01884740	Jun 2013 → Oct 2018	anaplastic astrocytoma, diffuse intrinsic pontine glioma, fibrillary astrocytoma, glioblastoma +2	Weill Medical College of Cornell University	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT01816984	May 2013 → Apr 2018	cancer of unknown primary site, hypopharynx squamous cell carcinoma, larynx verrucous carcinoma, metastatic squamous cell carcinoma +6	University of Chicago	Completed	No outcome recorded
Phase 1/2	NCT01760811	Jan 2013 → Dec 2015	squamous cell carcinoma	Rabin Medical Center	Unknown	No outcome recorded
Phase 1/2	NCT01602315	Nov 2012 → Sep 2016	head and neck squamous cell carcinoma	Novartis Pharmaceuticals	Terminated	Missed primary Stop: Enrollment
Phase 1/2	NCT01192087	Jun 2012 → Jul 2015	adenoid cystic carcinoma	Heidelberg University	Unknown	Missed primary
Phase 1/2	NCT01744340	May 2012 → Mar 2015	colorectal cancer, head and neck cancer	Howard Safran	Completed	No outcome recorded
Phase 1/2	NCT01611506	Feb → Dec 2012	gastric cancer	Dr Anna Dorothea Wagner	Terminated	No outcome recorded
Phase 1/2	NCT01468896	Oct 2011 → Sep 2015 overdue	head and neck squamous cell carcinoma	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 1/2	NCT01252628	Dec 2010 → Nov 2013	colorectal carcinoma, head and neck squamous cell carcinoma	Cascadian Therapeutics Inc.	Completed	No outcome recorded
Phase 1/2	NCT01086267	Jul 2010 → Aug 2011	colorectal cancer	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1/2	NCT01712919	May 2010 → Mar 2014	nasopharyngeal carcinoma	Jiangsu Cancer Institute & Hospital	Completed	No outcome recorded
Phase 1/2	NCT01166035	Mar 2010 → Sep 2011	cancer	Medical University Innsbruck	Unknown	No outcome recorded
Phase 1/2	NCT01015664	Feb 2010 → Dec 2012	head and neck squamous cell carcinoma	University of Tennessee Cancer Institute	Terminated	No outcome recorded
Phase 1/2	NCT01042028	Jan 2010 → Nov 2012	malignant pancreatic neoplasm	Per Pfeiffer	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT01077986	Aug 2009 → Aug 2010	malignant pancreatic neoplasm	Academic Medical Center - University of Amsterdam	Completed	No outcome recorded
Phase 1/2	NCT00927147	Jun 2009 → Jun 2013	head and neck cancer	Boneca Corporation	Terminated	No outcome recorded Stop: Business
Phase 1/2	NCT00972881	Apr 2009 → Dec 2011	rectal cancer	University College, London	Completed	No outcome recorded
Phase 1/2	NCT00778830	Feb 2009 → Apr 2014	colorectal cancer	Merck KGaA, Darmstadt, Germany	Completed	Missed primary
Phase 1/2	NCT00923299	Dec 2008 → Apr 2010	malignant pancreatic neoplasm	Institut du Cancer de Montpellier - Val d'Aurelle	Completed	No outcome recorded
Phase 1/2	NCT00714649	Jul 2008 → May 2011	head and neck squamous cell carcinoma	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	Completed	No outcome recorded
Phase 1/2	NCT00716456	Jul 2008 → May 2011	lung adenocarcinoma	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
Phase 1/2	NCT00704639	Apr 2008 → Dec 2014	head and neck cancer	Trans Tasman Radiation Oncology Group	Completed	No outcome recorded
Phase 1/2	NCT00660218	Mar 2008 → Dec 2016	squamous cell carcinoma	State University of New York - Upstate Medical University	Completed	No outcome recorded
Phase 1/2	NCT00815295	Jan 2008 → Jul 2013	squamous cell carcinoma	Duke University	Completed	No outcome recorded
Phase 1/2	NCT00570674	Nov 2007 → Oct 2013	adenosquamous carcinoma, basaloid squamous cell carcinoma, head and neck squamous cell carcinoma, undifferentiated carcinoma	Dana-Farber Cancer Institute	Terminated	No outcome recorded
Phase 1/2	NCT00544362	Jul 2007 → Jan 2011	esophageal cancer	Federation Francophone de Cancerologie Digestive	Completed	No outcome recorded
Phase 1/2	NCT00445861	Jan 2007 → Nov 2008	esophageal cancer	Swiss Cancer Institute	Completed	No outcome recorded
Phase 1/2	NCT00422773	Jan 2007 → Jun 2008	colorectal cancer	Technical University Dresden	Completed	No outcome recorded
Phase 1/2	NCT00353717	Nov 2006 → Sep 2009	breast carcinoma	Hadassah Medical Organization	Unknown	No outcome recorded
Phase 1/2	NCT00408499	Aug 2006 → Apr 2009	lung cancer	University of California, Davis	Completed	No outcome recorded
Phase 1/2	NCT00311857	Feb 2006 → ?	glioblastoma	Heidelberg University	Unknown	No outcome recorded
Phase 1/2	NCT00216203	May 2005 → Dec 2008	non-small cell lung carcinoma	Nasser Hanna, M.D.	Completed	No outcome recorded
Phase 1/2	NCT00101348	Jan 2005 → Oct 2007	adenoid cystic carcinoma, carcinoma of lip, esthesioneuroblastoma, hypopharynx squamous cell carcinoma +16	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1/2	NCT00226941	Jun 2004 → Mar 2008	rectal cancer	George Albert Fisher	Terminated	No outcome recorded
Phase 1/2	NCT01004731	Jun 2001 → Jan 2002	non-small cell lung carcinoma	University of Alabama at Birmingham	Completed	No outcome recorded
Phase 1/2	NCT00034541	Dec 2000 → May 2003	non-small cell lung carcinoma	Eli Lilly and Company	Completed	No outcome recorded

Phase 2432 trials · 16 met primary · 30 missed
Phase 2	NCT06418724	Oct 2026 → Jul 2030 expected	skin squamous cell carcinoma	Melanoma and Skin Cancer Trials Limited	Not yet recruiting	No outcome recorded
Phase 2	NCT07814417	Oct 2026 → Nov 2028 expected	colorectal neoplasm	Eli Lilly and Company	Not yet recruiting	No outcome recorded
Phase 2	NCT07815288	Sep 2026 → Dec 2029 expected	colorectal adenocarcinoma	Peking University Cancer Hospital & Institute	Not yet recruiting	No outcome recorded
Phase 2	NCT07659795	Jul 2026 → Jun 2027 expected	colorectal cancer	Verastem, Inc.	Recruiting	No outcome recorded
Phase 2	NCT07644559	Jun 2026 → Jun 2027 expected	pancreatic ductal adenocarcinoma	Verastem, Inc.	Recruiting	No outcome recorded
Phase 2	NCT07490119	Jun 2026 → Jun 2028 expected	colorectal cancer, susceptibility to, 4	Fudan University	Not yet recruiting	No outcome recorded
Phase 2	NCT07515963	Jun 2026 → Feb 2027 expected	colorectal cancer	Zhongnan Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT07621497	Jun 2026 → Jun 2029 expected	metastatic malignant neoplasm in the colon	Sun Yat-sen University	Not yet recruiting	No outcome recorded
Phase 2	NCT07554859	May 2026 → Apr 2027 expected	non-small cell lung carcinoma	Genfleet Therapeutics (Shanghai) Inc.	Not yet recruiting	No outcome recorded
Phase 2	NCT07581626	May 2026 → Apr 2027 expected	rectal cancer	Chinese PLA General Hospital	Not yet recruiting	No outcome recorded
Show all 432 trials opens the full record — a long page
Phase 2/311 trials · 1 met primary · 1 missed
Phase 2/3	NCT05710406	Aug 2023 → Jun 2034 expected	colon adenocarcinoma	Alliance for Clinical Trials in Oncology	Active not recruiting	No outcome recorded
Phase 2/3	NCT05063552	Mar 2023 → Dec 2027 expected	hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, lip and oral cavity squamous cell carcinoma, nasal cavity and paranasal sinus squamous cell carcinoma +5	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 2/3	NCT05409417	Oct 2022 → Feb 2024	metastasis from malignant tumor of colon	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
Phase 2/3	NCT02942706	Nov 2021 → Oct 2022	colorectal cancer	Ruijin Hospital	Unknown	No outcome recorded
Phase 2/3	NCT02978313	Nov 2016 → Nov 2019	colorectal cancer	Ruijin Hospital	Unknown	No outcome recorded
Phase 2/3	NCT02438722	May 2015 → Sep 2018	non-small cell lung carcinoma	SWOG Cancer Research Network	Completed	Missed primary
Phase 2/3	NCT01810913	Mar 2013 → Jan 2027	hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma	National Cancer Institute (NCI)	Suspended	No outcome recorded Stop: Enrollment
Phase 2/3	NCT01434394	Aug 2011 → Oct 2014	chemotherapy-induced toxicity, oral cavity cancer, oropharyngeal carcinoma	Shanghai Jiao Tong University School of Medicine	Completed	No outcome recorded
Phase 2/3	NCT00975897	Jul 2009 → Aug 2010	colorectal cancer	Medical Research Council	Completed	No outcome recorded
Phase 2/3	NCT01550055	May 2009 → Dec 2012	colorectal cancer	Shanghai Zhangjiang Biotechnology Limited Company	Completed	Met primary
Phase 2/3	NCT00509561	Feb 2008 → Sep 2012	esophageal cancer	Wales Cancer Trials Unit	Unknown	No outcome recorded

Phase 374 trials · 8 met primary · 19 missed
Phase 3	NCT07441681	Jan 2027 → Nov 2035 expected	head and neck squamous cell carcinoma, hypopharyngeal carcinoma, lip and oral cavity carcinoma, oropharyngeal carcinoma	NRG Oncology	Not yet recruiting	No outcome recorded
Phase 3	NCT07509099	Sep 2026 → Sep 2031 expected	head and neck squamous cell carcinoma	Ji Dongmei	Recruiting	No outcome recorded
Phase 3	NCT07549399	May 2026 → Apr 2029 expected	rectum adenocarcinoma	Sixth Affiliated Hospital, Sun Yat-sen University	Recruiting	No outcome recorded
Phase 3	NCT07432087	Feb 2026 → Dec 2030 expected	head and neck squamous cell carcinoma	Yue He, MD	Not yet recruiting	No outcome recorded
Phase 3	NCT07004413	Jan 2026 → Jan 2028 expected	colorectal cancer	Charite University, Berlin, Germany	Not yet recruiting	No outcome recorded
Phase 3	NCT07389265	Oct 2025 → Oct 2030 expected	colorectal cancer	University of Campania Luigi Vanvitelli	Recruiting	No outcome recorded
Phase 3	NCT06998069	Aug 2025 → Jun 2026 overdue	head and neck squamous cell carcinoma	Brown University	Recruiting	No outcome recorded
Phase 3	NCT06997497	Jul 2025 → Mar 2029 expected	colon adenocarcinoma, rectum adenocarcinoma	Merck Sharp & Dohme LLC	Recruiting	No outcome recorded
Phase 3	NCT06589804	Mar 2025 → Nov 2029 expected	hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma	National Cancer Institute (NCI)	Recruiting	No outcome recorded
Phase 3	NCT06647563	Nov 2024 → Sep 2029 expected	head and neck squamous cell carcinoma	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University	Not yet recruiting	No outcome recorded
Phase 3	NCT06616259	Sep 2024 → Sep 2028 expected	colorectal cancer	Meng Qiu	Not yet recruiting	No outcome recorded
Phase 3	NCT06496178	Jun 2024 → Feb 2028 expected	head and neck squamous cell carcinoma	Merus B.V.	Active not recruiting	No outcome recorded
Phase 3	NCT06226857	Jan 2024 → Dec 2026 expected	colorectal neoplasm	City Clinical Oncology Hospital No 1	Recruiting	No outcome recorded
Phase 3	NCT05948072	Jul 2023 → Jul 2026	metastasis from malignant tumor of colon	Fudan University	Unknown	No outcome recorded
Phase 3	NCT05797467	Apr 2023 → Apr 2030 expected	chemotherapy-induced toxicity, colorectal cancer	Sixth Affiliated Hospital, Sun Yat-sen University	Recruiting	No outcome recorded
Phase 3	NCT04966481	Apr 2022 → Feb 2029 expected	head and neck squamous cell carcinoma	Washington University School of Medicine	Recruiting	No outcome recorded
Phase 3	NCT04892173	Dec 2021 → Jun 2028 expected	squamous cell carcinoma	Johnson & Johnson Enterprise Innovation Inc.	Recruiting	No outcome recorded
Phase 3	NCT04793958	Jun 2021 → Jan 2026 overdue	colorectal cancer	Mirati Therapeutics Inc.	Active not recruiting	No outcome recorded
Phase 3	NCT04687631	Jan 2021 → Mar 2025 overdue	metastasis from malignant tumor of colon	Fudan University	Recruiting	No outcome recorded
Phase 3	NCT04835142	Dec 2020 → Mar 2023	colorectal cancer	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Completed	Met primary
Phase 3	NCT04607421	Dec 2020 → Mar 2025 overdue	neoplasm	Pfizer	Active not recruiting	Met primary
Phase 3	NCT04590963	Oct 2020 → May 2022 overdue	head and neck squamous cell carcinoma	AstraZeneca	Active not recruiting	Missed primary
Phase 3	NCT04525326	Oct 2020 → Oct 2022	metastasis from malignant tumor of colon	Fudan University	Unknown	No outcome recorded
Phase 3	NCT04509635	Sep 2020 → Aug 2022	metastasis from malignant tumor of colon	Fudan University	Unknown	No outcome recorded
Phase 3	NCT03803553	Apr 2020 → Dec 2026 expected	metastasis from malignant tumor of colon	Massachusetts General Hospital	Active not recruiting	No outcome recorded
Phase 3	NCT05540951	Jun 2018 → Aug 2022	colorectal cancer	Fudan University	Unknown	No outcome recorded
Phase 3	NCT03391934	Jan 2018 → Nov 2025	colorectal cancer	Cinnagen	Unknown	No outcome recorded
Phase 3	NCT03349710	Dec 2017 → Oct 2019	head and neck squamous cell carcinoma	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT03206151	Dec 2017 → May 2022	colorectal cancer	Taizhou Mabtech Pharmaceutical Co.,Ltd	Completed	Met primary
Phase 3	NCT02999087	Sep 2017 → Dec 2027 expected	head and neck squamous cell carcinoma	Groupe Oncologie Radiotherapie Tete et Cou	Active not recruiting	No outcome recorded
Phase 3	NCT02383966	Jul 2015 → Jan 2018	head and neck squamous cell carcinoma	Merck KGaA, Darmstadt, Germany	Completed	Met primary
Phase 3	NCT02934529	Mar 2015 → Jan 2025	colorectal cancer	Ludwig-Maximilians - University of Munich	Completed	No outcome recorded
Phase 3	NCT02484833	Feb 2015 → Dec 2019	—	Armando Orlandi	Completed	Mixed
Phase 3	NCT02633176	Jan 2015 → Jan 2023	nasopharyngeal carcinoma	Sun Yat-sen University	Unknown	No outcome recorded
Phase 3	NCT01884623	Nov 2013 → Oct 2021	head and neck squamous cell carcinoma	Gustave Roussy, Cancer Campus, Grand Paris	Completed	Missed primary
Phase 3	NCT01969877	Nov 2013 → Apr 2018	head and neck cancer	Lund University Hospital	Completed	Missed primary
Phase 3	NCT01910610	Oct 2013 → Jul 2023	colorectal cancer	GERCOR - Multidisciplinary Oncology Cooperative Group	Unknown	No outcome recorded
Phase 3	NCT01874171	Nov 2012 → Feb 2019	oropharynx squamous cell carcinoma	University of Warwick	Unknown	No outcome recorded
Phase 3	NCT01307878	Jun 2012 → Jun 2021	colorectal neoplasm, liver and intrahepatic bile duct neoplasm, metastatic neoplasm	Fudan University	Completed	No outcome recorded
Phase 3	NCT01228734	Sep 2010 → Jan 2016	colorectal cancer	Merck KGaA, Darmstadt, Germany	Completed	Met primary
Phase 3	NCT01167725	Aug 2010 → Jan 2012	colorectal cancer	Alliance for Clinical Trials in Oncology	Terminated	No outcome recorded
Phase 3	NCT01107639	May 2010 → Oct 2016	esophageal cancer, gastroesophageal junction adenocarcinoma	Swiss Cancer Institute	Completed	Missed primary
Phase 3	NCT00956007	Mar 2010 → Sep 2023 overdue	head and neck cancer	Radiation Therapy Oncology Group	Active not recruiting	Missed primary
Phase 3	NCT01177956	Dec 2009 → Jan 2011	head and neck squamous cell carcinoma	Merck KGaA, Darmstadt, Germany	Completed	No outcome recorded
Phase 3	NCT00999700	Sep 2009 → Dec 2016	head and neck squamous cell carcinoma	Gruppo Oncologico del Nord-Ovest	Unknown	No outcome recorded
Phase 3	NCT01030042	Sep 2009 → Apr 2015	colorectal cancer	Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente	Completed	No outcome recorded
Phase 3	NCT00946712	Jul 2009 → Aug 2017	lung adenocarcinoma, lung large cell carcinoma, squamous cell lung carcinoma	SWOG Cancer Research Network	Terminated	Missed primary
Phase 3	NCT01012258	Feb 2009 → Sep 2010	head and neck squamous cell carcinoma	Merck KGaA, Darmstadt, Germany	Completed	No outcome recorded
Phase 3	NCT00678535	Jun 2008 → Mar 2012	gastric cancer	Merck KGaA, Darmstadt, Germany	Completed	Missed primary
Phase 3	NCT00655876	Jun 2008 → Apr 2015	esophageal cancer	Radiation Therapy Oncology Group	Completed	Missed primary
Phase 3	NCT01086826	Mar 2008 → Apr 2014	head and neck squamous cell carcinoma	Associazione Volontari Pazienti Oncologici	Completed	No outcome recorded
Phase 3	NCT00533949	Nov 2007 → Jun 2013	lung carcinoma, radiation-induced disorder	Radiation Therapy Oncology Group	Completed	Missed primary
Phase 3	NCT01878422	Nov 2007 → Mar 2014	colorectal cancer	Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS	Completed	Missed primary
Phase 3	NCT00499369	Jun 2007 → Nov 2012	malignant colon neoplasm, rectal cancer	National Cancer Institute (NCI)	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00482222	Feb 2007 → Dec 2014	colorectal cancer, metastatic malignant neoplasm	University of Southampton	Unknown	No outcome recorded
Phase 3	NCT03362684	Nov 2005 → Nov 2009	colorectal cancer	IntegraGen SA	Completed	No outcome recorded
Phase 3	NCT00265811	Nov 2005 → Nov 2009	colorectal cancer	Federation Francophone de Cancerologie Digestive	Completed	Missed primary
Phase 3	NCT00265850	Nov 2005 → Feb 2015	colorectal cancer	Alliance for Clinical Trials in Oncology	Completed	Missed primary
Phase 3	NCT00265941	Nov 2005 → Jan 2011	head and neck cancer	Radiation Therapy Oncology Group	Completed	Missed primary
Phase 3	NCT00252564	Sep 2005 → Jun 2007	colorectal cancer	US Oncology Research	Completed	No outcome recorded
Phase 3	NCT00208546	Jun 2005 → Jul 2009	colorectal cancer	Dutch Colorectal Cancer Group	Completed	Missed primary
Phase 3	NCT00145314	May 2005 → May 2009	colorectal cancer	The Nordic Colorectal Cancer Biomodulation Group	Completed	No outcome recorded
Phase 3	NCT00182715	Mar 2005 → May 2009	colorectal cancer	Velindre NHS Trust	Unknown	Missed primary
Phase 3	NCT00095199	Jan 2005 → Jul 2011	non-small cell lung carcinoma	Eli Lilly and Company	Completed	Missed primary
Phase 3	NCT00122460	Dec 2004 → Mar 2007	head and neck cancer	Merck KGaA, Darmstadt, Germany	Completed	Met primary
Phase 3	NCT00148798	Oct 2004 → Jul 2007	non-small cell lung carcinoma	Merck KGaA, Darmstadt, Germany	Completed	Met primary
Phase 3	NCT00154102	May 2004 → Dec 2006	colorectal cancer	Merck KGaA, Darmstadt, Germany	Completed	Mixed
Phase 3	NCT00079274	Feb 2004 → Nov 2012	colon adenocarcinoma	National Cancer Institute (NCI)	Completed	Missed primary
Phase 3	NCT00075686	Jan 2004 → May 2007	pancreatic adenocarcinoma	SWOG Cancer Research Network	Completed	Missed primary
Phase 3	NCT00079066	Dec 2003 → Nov 2006	colorectal cancer	NCIC Clinical Trials Group	Completed	Met primary
Phase 3	NCT00077233	Dec 2003 → Dec 2006	colorectal cancer	Alliance for Clinical Trials in Oncology	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00063141	Apr 2003 → Jun 2006	colorectal cancer	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00061815	Mar 2003 → Dec 2004	colorectal cancer	Eli Lilly and Company	Completed	No outcome recorded
Phase 3	NCT00003809	Aug 1999 → Sep 2004	head and neck cancer	Eastern Cooperative Oncology Group	Completed	Missed primary

Phase 45 trials · 1 met primary
Phase 4	NCT07094893	Apr 2026 → Mar 2028 expected	colorectal cancer	Gruppo Oncologico del Nord-Ovest	Not yet recruiting	No outcome recorded
Phase 4	NCT05203172	Jul 2022 → Jul 2029 expected	cancer	Pfizer	Recruiting	No outcome recorded
Phase 4	NCT01315990	Jan 2011 → Mar 2015	colorectal cancer	Dr. Carl Schimanski	Unknown	No outcome recorded
Phase 4	NCT01564810	Sep 2006 → Jun 2012	colorectal adenocarcinoma, metastatic malignant neoplasm	Xu jianmin	Unknown	Met primary
Phase 4	NCT00327093	May 2006 → Oct 2008	colorectal cancer, metastatic neoplasm	Hospices Civils de Lyon	Terminated	No outcome recorded
Phase not applicable19 trials
—	NCT06199232	Jan 2024 → Jun 2026 overdue	metastasis from malignant tumor of colon	Peking University	Active not recruiting	No outcome recorded
—	NCT06035133	Nov 2023 → Nov 2024 overdue	rectal cancer	Tang-Du Hospital	Not yet recruiting	No outcome recorded
—	NCT05963087	Aug 2023 → Feb 2025	colorectal cancer	Zhejiang Cancer Hospital	Unknown	No outcome recorded
—	NCT05873972	Jun 2023 → Jun 2024	metastasis from malignant tumor of colon	Fudan University	Unknown	No outcome recorded
—	NCT05978349	Feb 2022 → Sep 2025	colorectal cancer	Peking Union Medical College Hospital	Unknown	No outcome recorded
—	NCT05424692	Sep 2021 → Sep 2025 overdue	chemotherapy-induced toxicity, colon carcinoma, rectal carcinoma	Peking Union Medical College Hospital	Recruiting	No outcome recorded
—	NCT02177838	Mar 2015 → Aug 2019	hypopharynx squamous cell carcinoma, larynx verrucous carcinoma, oropharynx squamous cell carcinoma, tongue cancer	Rutgers, The State University of New Jersey	Terminated	No outcome recorded Stop: Enrollment
—	NCT02324608	Jan 2015 → Dec 2020	skin squamous cell carcinoma	Rutgers, The State University of New Jersey	Completed	No outcome recorded
—	NCT02241187	Sep 2014 → Sep 2016	pancreatic adenocarcinoma	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded
—	NCT01631539	Sep 2012 → Dec 2014	metastasis from malignant tumor of colon	Universitaire Ziekenhuizen KU Leuven	Withdrawn	No outcome recorded Stop: Enrollment
—	NCT01790516	May 2012 → Mar 2013	head and neck squamous cell carcinoma	Georgetown University	Terminated	No outcome recorded Stop: Enrollment
—	NCT01663259	Jan 2011 → Sep 2019	human papilloma virus infection, oropharynx squamous cell carcinoma	University of Michigan Rogel Cancer Center	Completed	No outcome recorded
—	NCT01280643	Mar 2010 → Jul 2013	colorectal cancer	Fox Chase Cancer Center	Terminated	No outcome recorded Stop: Enrollment
—	NCT01366118	Oct 2009 → Apr 2011	rectal carcinoma	Grupo Hospital de Madrid	Completed	No outcome recorded
—	NCT00891904	Apr 2009 → Jul 2011	head and neck cancer	Roswell Park Cancer Institute	Terminated	No outcome recorded Stop: Enrollment
—	NCT00502463	Oct 2007 → Jan 2010	head and neck cancer	Austrian South Oncology Group	Completed	No outcome recorded
—	NCT00430027	Nov 2006 → Aug 2008	esophageal adenocarcinoma	University of Colorado, Denver	Terminated	No outcome recorded Stop: Enrollment
—	NCT00448838	May 2006 → Aug 2007	malignant pancreatic neoplasm	University of Miami	Completed	No outcome recorded
—	NCT00084773	Mar 2004 → Jan 2007	colorectal cancer	Memorial Sloan Kettering Cancer Center	Completed	No outcome recorded

Comparator or background therapy255 trials
Phase 0	NCT07318389 Background	Jun 2026 → Nov 2027 expected	colorectal cancer	M.D. Anderson Cancer Center	Not yet recruiting	No outcome recorded
Phase 0	NCT06011772 Background	Dec 2023 → Feb 2026 overdue	colorectal cancer	Roswell Park Cancer Institute	Active not recruiting	No outcome recorded
Phase 1	NCT07672483 Background	Oct 2026 → Jan 2028 expected	cancer or benign tumor	National Cancer Institute (NCI)	Recruiting	No outcome recorded
Phase 1	NCT07813468 Comparator	Sep 2026 → Jun 2027 expected	—	HC Biopharma Inc.	Recruiting	No outcome recorded
Phase 1	NCT07217028 Background	Apr 2026 → Apr 2029 expected	head and neck squamous cell carcinoma	Vanderbilt-Ingram Cancer Center	Recruiting	No outcome recorded
Show all 255 trials opens the full record — a long page

Press releases naming this drug 61 releases

Date	Issuer	Release
2026-09-30	Hummingbird Bioscience	Hummingbird Bioscience Announces First Patient Dosed in Phase II Trial of HMBD-001 and Cetuximab in Advanced Squamous Cell Cancers hummingbirdbioscience.com ↗
2026-07-14	Merck KGaA, Darmstadt, Germany	European Commission Approves Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX for First-Line Treatment of Metastatic Colorectal Cancer with BRAF V600E Mutation emdgroup.com ↗
2026-07-08	Shanghai Henlius Biotech	First Patient Dosed in China for Phase 1 Clinical Trial of Henlius’ Cetuximab Biosimilar HLX05-N henlius.com ↗
2026-05-10	Shanghai Henlius Biotech	Globalisation 2.0 \| U.S. FDA Clearance of IND for Cetuximab Biosimilar HLX05-N henlius.com ↗
2026-04-14	Shanghai Henlius Biotech	NMPA Grants IND Approval for Henlius' Cetuximab Biosimilar HLX05-N henlius.com ↗
2025-02-07	Klus Pharma Inc.	Kelun-Biotech’s Product Cetuximab N01 Injection Approved For Marketing By NMPA Of China kluspharma.com ↗
2024-10-29	Biond Biologics	Biond Biologics Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany to Evaluate BND-35 in Combination with Cetuximab in a Phase 1 Clinical Study biondbio.com ↗
2024-06-26	Jiangsu Simcere Pharmaceutical Co., Ltd.	Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA simcere.com ↗
2024-06-21	Bristol-Myers Squibb	Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) bms.com ↗
2024-04-08	Bristol-Myers Squibb	KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) bms.com ↗
2024-02-27	Purple Biotech Ltd.	Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024 purple-biotech.com ↗
2024-02-20	Bristol-Myers Squibb	U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for KRAZATI® (adagrasib) in Combination with Cetuximab as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or... bms.com ↗
2024-01-16	AVEO Pharmaceuticals, Inc.	AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) aveooncology.com ↗
2023-09-11	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	The first of its kind in China! Kelun-Biotech's Cetuximab Solution for Infusion Accepted for market registration application by the National Medical Products Administration. kelun-biotech.com ↗
2023-08-22	Jiangsu Simcere Pharmaceutical Co., Ltd.	Simcere Zaiming Partners with MabPharm on anti-EGFR Monoclonal Antibody CMAB009 in China simcere.com ↗
2023-06-02	Innovent Biologics (Suzhou) Co. Ltd.	Innovent Enters into Clinical Trial Collaboration with Merck KGaA, Darmstadt, Germany Investigating Combination Therapy of IBI351 (KRASG12C Inhibitor) and Cetuximab (ERBITUX®)for KRASG12C-mutated NSCLC in China innoventbio.com ↗
2023-05-29	Enzene Biosciences Ltd.	Enzene Biosciences launches Cetuximab enzene.com ↗
2023-04-18	Erasca, Inc.	Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting erasca.com ↗
2023-01-21	Wugen, Inc.	Wugen Presents Data on WU-NK-101 in Combination with Cetuximab in Preclinical Models of Advanced Colorectal Cancer (CRC) at ASCO Gastrointestinal Cancers Symposium wugen.com ↗
2023-01-19	SOTIO a.s.	SOTIO Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination with Cetuximab sotio.com ↗
2022-07-18	Erasca, Inc.	Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 and Cetuximab Combination erasca.com ↗
2022-06-22	AVEO Pharmaceuticals, Inc.	AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCC aveooncology.com ↗
2022-03-10	Erasca, Inc.	Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-007 and Cetuximab Combination erasca.com ↗
2022-01-04	AVEO Pharmaceuticals, Inc.	AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany to Evaluate Ficlatuzumab and ERBITUX® (cetuximab) in Patients with Recurrent or Metastatic HNSCC aveooncology.com ↗
2021-12-09	Innate Pharma	Monalizumab combined with cetuximab and durvalumab demonstrates anti-tumor activity in first-line recurrent or metastatic head and neck cancer at ESMO Immuno-Oncology 2021 Congress innate-pharma.com ↗
2021-09-28	Eli Lilly and Company	FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy lilly.com ↗
2021-05-19	AVEO Pharmaceuticals, Inc.	AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC aveooncology.com ↗
2021-04-13	NKGen Biotech, Inc.	NKMax and Merck KGaA, Darmstadt, Germany Expand Clinical Collaboration to Include Phase I/IIa Trial Investigating the Combination of SNK01 with ERBITUX® (cetuximab) in Metastatic NSCLC nkgenbiotech.com ↗
2020-12-15	Nektar Therapeutics	Nektar Therapeutics Announces Dosing of First Patients in Phase 1/2 Study of its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma or Colorectal Cancer nektar.com ↗
2020-12-03	Innate Pharma	Innate Pharma to present additional efficacy data for monalizumab in combination with cetuximab in head and neck cancer at the ESMO immuno-oncology virtual congress innate-pharma.com ↗
2020-06-02	NKGen Biotech, Inc.	NKMax America Receives FDA Clearance of IND for Phase I/2a Trial of their Natural Killer Cell Therapy (SNK01) in Combination with Trastuzumab or Cetuximab for the Treatment of Advanced/Metastatic HER2- or EGFR- Expressing Cancers nkgenbiotech.com ↗
2020-05-14	Innate Pharma	Innate Pharma to present new efficacy data for monalizumab in combination with cetuximab in Head and Neck Cancer at the ASCO20 Virtual Scientific Program innate-pharma.com ↗
2020-04-08	Pfizer	U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy pfizer.com ↗
2020-03-02	Merck KGaA, Darmstadt, Germany	ERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) prnewswire.com ↗
2019-12-18	Pfizer	U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI® (encorafenib) in Combination with ERBITUX® (cetuximab) (BRAFTOVI Doublet) for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer After Prior Therapy pfizer.com ↗
2019-09-29	Pfizer	Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer pfizer.com ↗
2018-11-12	Innate Pharma	SITC 2018: further analyses of the Phase II study of the combination of monalizumab and cetuximab in head and neck patients show encouraging survival data in both subgroups of IO-naïve and IO-pretreated SCCHN patients innate-pharma.com ↗
2018-10-20	Innate Pharma	Innate Pharma announces Phase II results from monalizumab and cetuximab combination in head and neck cancer at the ESMO 2018 Congress innate-pharma.com ↗
2018-09-26	Purple Biotech Ltd.	Kitov to Present Data on NT219 in Combination with Keytruda® and Erbitux® at AACR International Cancer Immunotherapy Conference purple-biotech.com ↗
2018-04-17	Innate Pharma	Preliminary data suggest promising anti-tumor activity of the combination of monalizumab and cetuximab in patients with platinum pretreated SCCHN innate-pharma.com ↗
2017-03-02	Merck KGaA, Darmstadt, Germany	NICE Expands Positive Recommendation for Erbitux as First-line Treatment for RAS Wild-type mCRC prnewswire.com ↗
2016-04-25	Merck KGaA, Darmstadt, Germany	Phase III TAILOR Landmark Study Demonstrates Significant Benefits of Erbitux in Combination with FOLFOX Over FOLFOX Alone prnewswire.com ↗
2015-04-16	Bristol-Myers Squibb	Lilly, Bristol-Myers Squibb Restructure Erbitux® (cetuximab) Collaboration in North America bms.com ↗
2015-04-16	Eli Lilly and Company	Lilly, Bristol-Myers Squibb Restructure Erbitux® (cetuximab) Collaboration in North America lilly.com ↗
2012-07-06	Bristol-Myers Squibb	FDA Approves ERBITUX(R) (cetuximab) as First-Line Treatment in KRAS Mutation-Negative (Wild-Type) Epidermal Growth Factor Receptor (EGFR)-Expressing Metastatic Colorectal Cancer in Combination with FOLFIRI (Irinotecan, 5-Fluorouracil, Leucovorin) bms.com ↗
2012-07-06	Eli Lilly and Company	FDA Approves ERBITUX(R) (cetuximab) as First-Line Treatment in KRAS Mutation-Negative (Wild-Type) Epidermal Growth Factor Receptor (EGFR)-Expressing Metastatic Colorectal Cancer in Combination with FOLFIRI (Irinotecan, 5-Fluorouracil, Leucovorin) lilly.com ↗
2011-11-08	Bristol-Myers Squibb	FDA Approves ERBITUX® (cetuximab) for First-Line Recurrent Locoregional or Metastatic Head and Neck Cancer in Combination with Platinum-based Chemotherapy with 5-Fluorouracil bms.com ↗
2011-11-07	Eli Lilly and Company	FDA Approves ERBITUX® (cetuximab) for First-Line Recurrent Locoregional or Metastatic Head and Neck Cancer in Combination with Platinum-based Chemotherapy with 5-Fluorouracil lilly.com ↗
2009-09-23	Bristol-Myers Squibb	Data Presented from Two Phase 3 ERBITUX® Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress bms.com ↗
2009-07-20	Bristol-Myers Squibb	ImClone Systems and Bristol-Myers Squibb Announce Revisions to ERBITUX® (cetuximab) U.S. Product Labeling for Metastatic Colorectal Cancer bms.com ↗
2009-03-02	Bristol-Myers Squibb	ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX® in U.S. bms.com ↗
2009-03-02	Eli Lilly and Company	ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX®in U.S. lilly.com ↗
2009-01-23	Bristol-Myers Squibb	ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplemental Biologics Application Submission for ERBITUX® bms.com ↗
2009-01-23	Eli Lilly and Company	ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplemental Biologics Application Submission for ERBITUX® lilly.com ↗
2008-12-08	Bristol-Myers Squibb	ERBITUX® Supplemental Biologics License Application for Advanced Non-Small Cell Lung Cancer Submitted to U.S. Food and Drug Administration bms.com ↗
2008-10-30	Bristol-Myers Squibb	ERBITUX(R) Supplemental Biologics License Application for First-Line Recurrent or Metastatic Head and Neck Cancer Accepted for Priority Review by U.S. Food and Drug Administration bms.com ↗
2008-10-22	Bristol-Myers Squibb	Study Published in New England Journal of Medicine Shows K-ras Gene Mutation Status May Affect Response to ERBITUX(R) Treatment bms.com ↗
2008-10-06	Bristol-Myers Squibb	Bristol-Myers Squibb Comments on Eli Lilly as New Erbitux Marketing Partner bms.com ↗
2008-09-22	Bristol-Myers Squibb	ERBITUX(R) Five-Year Data Show Significant Improvement in Overall Survival for Patients with Locally or Regionally Advanced Head and Neck Cancer bms.com ↗
2008-09-10	Bristol-Myers Squibb	Study Published in New England Journal of Medicine Shows ERBITUX(R) Improved Survival in First-Line Recurrent And/Or Metastatic Head and Neck Cancer bms.com ↗
2008-05-31	Bristol-Myers Squibb	ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer bms.com ↗

Evidence & citations 23 cited values

Every value below carries the sentence it was read from. 1,039 sources stand behind the page.

Field	Value	Cited text
Known as	Cetuximab	“Investigator's choice of standard first-line systemic therapy for initially unresectable colorectal cancer, including chemotherapy (e.g., FOLFOX, FOLFIRI, CAPOX) with or...” NCT07509398 ↗ 1015 “Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil +...” NCT05978349 ↗ “Tivantinib 360 mg twice daily in combination with other anti-cancer therapy (eg, erlotinib,sorafenib, pemetrexed, docataxel, gemcitabine, irinotecan, and/or cetuximab) at the...” NCT01178411 ↗ “During cycle I (chemoradiation), gemcitabine (200 mg/m2) and cetuximab 400mg/m2 initial dose followed by 250mg/m2 IV weekly will be given with continuous infusion 5-FU (200...” NCT00424827 ↗ “The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third...” NCT03077243 ↗ “Eligible subjects will be treated with tivantinib (ARQ 197) at a dose of 360 mg twice daily (a total daily dose of 720 mg) orally in a continuous manner and cetuximab (Erbitux)...” NCT01892527 ↗ “A Randomized, Single Intravenous Dose, Parallel Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX05 Vs. Erbitux®...” NCT06980454 ↗ “Drug: cetuximab 400 mg/m2 for the first dose, then 250 mg/sqm, intravenous infusion, repeated weekly; or Cetuximab 500 mg/ sqm, intravenous infusion, D1, repeated every 2 weeks.” NCT05652894 ↗ “Cetuximab 400mg/m2 will be used one week before radiotherapy and 250mg/m2/week during IMRT, or nimotuzumab 200mg/week; meanwhile, cisplatin 80mg/m2 will be used every 3 weeks.” NCT04508829 ↗ “First-line standard systemic therapies in cohort A include: FOLFOX/FOLIRI/XELOX+ bevacizumab, FOLFOX/FOLIRI/XELOX+cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only).” NCT06841159 ↗ “* Cetuximab (only for patients with K-ras wild type and positive EGFR mutation) 400 mg/m2 IV over 2 hrs on Day 1, and 250 mg/m2 IV over 1 hr on Day 8, 15, 22, 29, and 36.” NCT01923987 ↗ Show 1,005 more sources
Known as	C-225	“A Phase III Randomized Study of Cetuximab (Erbitux™, C225) and Best Supportive Care Versus Best Supportive Care in Patients With Pretreated Metastatic Epidermal Growth Factor...” NCT00079066 ↗ 16 “A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic...” NCT00056030 ↗ “A Phase II Trial of Cetuximab (c225) as Therapy for Recurrent Non-Small Cell Lung Cancer in Patients Who Have Received Prior Therapy With Tyrosine Kinase Inhibitor Directed...” NCT00694603 ↗ “Cetuximab (C225) and Radiation in Elderly and /or Poor Performance Status Patients With Locally Advanced Non-Small Cell Lung Cancer: A Phase II Study to Evaluate Survival and Toxicity” NCT00124618 ↗ “This is an open, multicenter phase Ⅱ clinical trial on cetuximab (C225) combined with IMRT + concurrent chemotherapy of cisplatin in locoregionally advanced nasopharyngeal carcinoma.” NCT00700440 ↗ “A Phase I Trial of Tailored Radiation Therapy With Concomitant Cetuximab (C225, NSC #714692) and Cisplatin (NSC #119875) in the Treatment of Patients With Cervical Cancer” NCT00104910 ↗ “C225 = Cetuximab: 400 mg/m2 IV will be given as the initial OR loading dose in week 1 and then 250 mg/m2 IV weekly will be given for 8 weeks (weeks 2-9).” NCT00343083 ↗ “Cetuximab (C-225), a Chimeric Monoclonal Antibody Against the Epidermal Growth Factor Receptor (EGFR)” NCT00820417 ↗ “Cetuximab (C225) is a human/murine chimeric monoclonal antibody directed to the EGFR binding site.” NCT00536614 ↗ “cetuximab (C225), an antibody that inhibits epidermal growth factor receptor (EGFR) activity” PMID 21329967 ↗ Feb 2011 “Pre-RT cetuximab (C225), 400 mg/m²IV and weekly C225, 250 mg/m2 IV in during RT.” NCT01758731 ↗ Show 6 more sources
Known as	Cetux	“The BEACON CRC study demonstrated that encorafenib (Enco)+cetuximab (Cetux)±binimetinib (Bini) significantly improved overall survival (OS) versus” PMID 39313594 ↗ Sep 2024
Known as	cetuxiamb	“EGFR antibodies panitumumad and cetuxiamb in case of KRAS wild-type tumors.” NCT02314182 ↗
Known as	Cetuximab (C225, Erbitux by Merck)	“Cetuximab (C225, Erbitux by Merck)” NCT00422773 ↗
Known as	Cetuximab (C225, Erbitux)	“Cetuximab (C225, Erbitux)” NCT00580073 ↗
Known as	Cetuximab (Erbitux)	“Cetuximab (Erbitux)” NCT01192087 ↗ 2 “Cetuximab (Erbitux)” NCT01181401 ↗ “Cetuximab (Erbitux)” NCT01309126 ↗
Known as	Cetuximab Beta	“Camrelizumab 200 mg (Day 1) intravenous infusion (IV), Cetuximab Beta 400 mg/m² (Day 1) IV, followed by 250 mg/m² IV weekly, with a 21-day cycle for 2 cycles; followed by...” NCT07432087 ↗
Known as	Cetuximab Beta Injection	“Cetuximab Beta Injection 500mg/㎡ IV, q14d” NCT07294261 ↗
Known as	Cetuximab or c225	“Cetuximab or c225” NCT05959356 ↗
Known as	cetuximab β	“Despite this established approach, cetuximab β (CMAB009), as a modified antibody of cetuximab, prospectively selected for dual RAS/BRAF wild-type patients, has not yet been...” PMID 40328753 ↗ May 2025
Known as	Cetuximab(C225, Erbitux, Merck KGaA)	“Cetuximab(C225, Erbitux®, Merck KGaA)” NCT00153998 ↗
Known as	CMAB009	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03206151 ↗ 1 NCT01550055 ↗
Known as	CTX	“GBM often has a high expression EFGR (Epidermal Growth Factor Receptor) which is blocked by Cetuximab (CTX).” NCT02861898 ↗ 3 “an epidermal growth factor receptor inhibitor cetuximab (CTX) added to the concurrent therapy” NCT00343083 ↗ “intracranial superselective intra-arterial infusion of Cetuximab (CTX), at a dose of 250mg/m2” NCT02800486 ↗ “cetuximab (CTX) or nimotuzumab (NTZ)” NCT04508816 ↗
Known as	Erbitux	“the rationale of the combination of lenalidomide with a therapeutic IgG1 antibody such as cetuximab (Erbitux®) is based on the fact that several reports suggest a role of...” NCT01166035 ↗ 58 “A Phase Ib Open-label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux®) in Patients With Non-small cell Lung Cancer With...” NCT01090011 ↗ “A Phase III Randomized Study of Cetuximab (Erbitux™, C225) and Best Supportive Care Versus Best Supportive Care in Patients With Pretreated Metastatic Epidermal Growth Factor...” NCT00079066 ↗ “Eligible subjects will be treated with tivantinib (ARQ 197) at a dose of 360 mg twice daily (a total daily dose of 720 mg) orally in a continuous manner and cetuximab (Erbitux)...” NCT01892527 ↗ “Cetuximab (ErbituxTM) is designed to prevent or slow down the growth of cancer cells by blocking proteins inside the cancer cell, called the epidermal growth factor receptor (EGFR).” NCT00543504 ↗ “The purpose of this study is to investigate whether cetuximab (Erbitux®) with cisplatin and capecitabine (Xeloda) as 1st line treatment in the advanced gastric cancer is effective.” NCT00477711 ↗ “Cetuximab (Erbitux®) is a recombinant chimeric human/mouse Immunoglobulin G monoclonal antibody which binds to EGFR and competitively inhibits the binding of EGFR and other ligands” NCT06599502 ↗ “A Phase I-IIa Dose-Ranging Study of Pemetrexed (Alimta) Plus Cetuximab (Erbitux) in Patients With Recurrent Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN04-79” NCT00216203 ↗ “The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes” NCT01102231 ↗ “Erbitux: 400 mg/m2 as a loading dose one week prior to radiation and taxotere, and then at 250 mg/m2 given weekly on Day 1 of treatment week following Taxotere.” NCT01794845 ↗ “Cetuximab (Erbitux® )- Cetuximab is a recombinant IgG1 chimeric monoclonal antibody directed against human epidermal growth factor receptor (EGFR).” NCT01315990 ↗ Show 48 more sources
Known as	ERBITUX (cetuximab)	“ERBITUX (cetuximab)” NCT00517829 ↗ 1 “Erbitux (cetuximab)” NCT00931840 ↗
Known as	ErbituxÒ	“Cetuximab (ErbituxÒ) (Arm B only) every two weeks:” NCT00552149 ↗
Known as	IMC-C225	“Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine” NCT00075686 ↗ 1 “IMC-C225” NCT00980239 ↗
Known as	NSC #714692	“A Phase I Trial of Tailored Radiation Therapy With Concomitant Cetuximab (C225, NSC #714692) and Cisplatin (NSC #119875) in the Treatment of Patients With Cervical Cancer” NCT00104910 ↗ 1 “cetuximab (C225, NSC #714692) in Combination With Carboplatin (NSC #241240)” NCT00086892 ↗
Action	Inhibit	“the monoclonal antibody EGFR inhibitor, cetuximab” PMID 16246975 ↗ Oct 2005
Modality	Monoclonal antibody	“We conducted a multinational, randomized study to compare radiotherapy alone with radiotherapy plus cetuximab, a monoclonal antibody against the epidermal growth factor...” PMID 16467544 ↗ Feb 2006
Route	Intravenous	“Patients receive maintenance cetuximab IV over 1 hour on day 8.” NCT00004227 ↗
Target	EGFR	“Phase II Study of Cetuximab Anti-Epidermal Growth Factor Receptor (EGFr) Antibody” NCT00004865 ↗